-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Managing Side Effects: Guidance for Use of Immunotherapies in Multiple Myeloma

Program: Education Program
Session: How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies
Hematology Disease Topics & Pathways:
Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Adverse Events
Monday, December 11, 2023, 10:30 AM-11:45 AM

Surbhi Sidana, MD

Stanford University School of Medicine, Stanford, CA

Disclosures: Sidana: Magenta Therapeutics, BMS, Janssen, Sanofi, Oncopeptides, Takeda, Pfizer: Consultancy; Magenta Therapeutics, BMS, Allogene, Janssen, Novartis: Research Funding.

OffLabel Disclosure:

<< Previous Presentation | Next Presentation